312 results about "Intestinal microorganisms" patented technology

A database structure obtained by means of information retrieval, and a reasoning system, which structure and system specifically relate to a gut microbe knowledge graph system, comprising: a gut microbe knowledge graph consisting of a gut microbe knowledge base, a gut microbe and small-molecule drug therapy association knowledge base, and a clinical medicine database; and a multimodal uncertainty reasoning system, using the gut microbe knowledge graph. The gut microbe knowledge graph system predicts potential diseases, drugs, genes, etc., which are associated with gut microbes.

The invention discloses a triggering probiotic-drug conjugate and a preparation method and application thereof, and belongs to the technical field of oral drug delivery systems, the triggering probiotic-drug conjugate comprises probiotics, an adhesive inner layer formed by coordination of tannic acid and Fe < 3 + >, and an outer layer formed by pterostilbene-phospholipid bridged by ROS-responsive thioether bonds and cholesterol; the inner layer coats the surfaces of the probiotics through coordination, and the outer layer coats the outer part of the inner layer through self-assembly. An outer lipid layer is decomposed under high-concentration ROS in an inflammation colon area, and probiotics coated with pterostilbene and a tannic acid layer are released. Pterostilbene relieves inflammation and rebuilds a pathological microenvironment, and catechol groups in a tannic acid layer and the surface of the intestinal tract generate multiple interactions to promote planting of probiotics. In UC mouse models, the conjugates exhibit enhanced therapeutic effects by inhibiting inflammation, restoring intestinal barrier function, and improving intestinal microbiota homeostasis. The invention has important transformation potential in clinical application of gastrointestinal diseases.

Provided are a mixture of three species of Lactobacillus fermentum strain and Lactobacillus plantarum strain and use thereof. A composition according to one aspect including, as an active ingredient, a mixture of Lactobacillus fermentum strains GB102 and GB103 and Lactobacillus plantarum strain GB104; or a lysate or culture solution thereof, or an extract of the culture solution, can be usefully used for the prevention or treatment of muscle-related disorders or obesity by alleviating the decrease in grip strength induced by aging or reducing the change in intestinal microbial environment induced by aging.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum GL-2 and application thereof. The invention provides a strain of lactobacillus plantarum which is preserved in the 8th road of Wuchang District in Wuhan City, Hubei Province on March 15, 2023, and the preservation number is CCTCC M 2023328. The results of the embodiment show that the lactobacillus plantarum GL-2 provided by the invention has the effects of reducing blood sugar and blood fat, and the lactobacillus plantarum GL-2 provided by the invention also has the effects of repairing inflammation damaged organs and regulating intestinal microorganisms.

The invention discloses application of animal bifidobacterium subsp. Lactis GOLDGUT-BB21 in preparation of products for relieving depression, and belongs to the technical field of biological medicine. The probiotics disclosed by the invention can be used for relieving depressive symptoms, improving related symptoms, assisting in treating depression and preventing depression, and also can be used as a nutritional supplement to help maintain the balance of intestinal microflora and promote intestinal health.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention discloses an intestinal microbial marker related to non-alcoholic fatty liver, a product and application of the intestinal microbial marker, and belongs to the field of biological medicine. The microbial marker is prepared from one or more of streptococcus anginiae, bacteroides faecalis, bifidobacterium adolescentis and hispidaceae bacteria. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the microbial marker. The invention further provides a product for diagnosing the non-alcoholic fatty liver disease, a prediction system for evaluating the risk that a to-be-detected object is a patient with the non-alcoholic fatty liver disease, and a computer program product related to the non-alcoholic fatty liver disease. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of the non-alcoholic fatty liver disease, and provides a new tool for clinical diagnosis.

Various benefits to intestinal health are made by delivery of an active agent to the colon of an animal, including a human. Active ingredients include of riboflavin, vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, β-carotene, vitamin B1, niacin, vitamin B5, vitamin B6, biotin, vitamin B12, omega-3 fatty acids and combinations thereof. Benefits include increased concentration of at least one short-chain fatty acid its salt thereof in the intestine, increased microbiome diversity in the intestine, increased beneficial bacteria in the intestine, increased the butyrate synthesis pathway in the intestine, improved barrier function of the intestine, reduced redox potential of the gut, reduced amount of gas produced in the intestine; and stimulation of intestinal immune responses.

The invention provides a composition for promoting differentiation of intestinal immune cells as well as a preparation method and application of the composition. According to the composition, 1, 3-dioleic acid-2-palmitic acid triglyceride and breast milk oligosaccharide are used in a combined manner, so that monocytes can be effectively promoted to differentiate into intestinal macrophages, and inflammation is reduced to a certain extent. After the monocytes are differentiated into the intestinal macrophages, the intestinal immune homeostasis and intestinal microbiota inflammatory response can be regulated, so that the mucosal immune homeostasis and intestinal epithelial cell barrier function are maintained. Therefore, the composition provided by the invention can improve the intestinal immune barrier by promoting the monocytes to differentiate into the intestinal macrophages, and provides a new thought for improving the early intestinal barrier of infants through nutritional supplement.

The invention belongs to the technical field of biological medicine, and relates to application of a clerodendranthus spicatus tea bag in regulating intestinal excretion and reducing uric acid. One of the purposes of the invention is to provide the application of the clerodendranthus spicatus teabag in regulating intestinal tracts to reduce uric acid According to a preferred embodiment, the clerodendranthus spicatus teabag regulates ATP binding cassette transporter G2 and inhibits uricase activity. The invention provides the application of the clerodendranthus spicatus teabag in regulating the intestinal microbial environment and reducing uric acid, and the clerodendranthus spicatus teabag has remarkable beneficial effects. The clerodendranthus spicatus teabag can effectively regulate the structure and the function of intestinal microflora, especially the enrichment amount of characteristic bacteria Muriaculum in the intestinal tract, further strengthens the probiotic activity of the intestinal flora, and is helpful for maintaining the steady state of uric acid in the body. The multi-way synergistic effect not only provides an innovative strategy for preventing and treating hyperuricemia and related metabolic diseases, but also avoids side effects possibly brought by traditional medicines, and shows good application prospects and clinical values.

The invention belongs to the technical field of medical diagnosis, and provides an HIV (human immunodeficiency virus) combined non-alcoholic fatty liver diagnosis and prediction marker and application. The marker comprises 39 biomarkers in total, wherein the 39 biomarkers comprise two intestinal microorganisms of enterobacter and klebsiella and 37 plasma metabolites of diacylglycerol, lysophosphatidic acid and the like; by integrating microbiome and metabonomics, the multi-dimensional marker is screened and verified, so that the problems of lack of high specificity and sensitivity, difficulty in early disease screening and incapability of effective risk assessment of an HIV (Human Immunodeficiency Virus) combined NAFLD (Non-Amplified Fragment Leukemia) early diagnosis method caused by unknown pathogenesis in the prior art are solved; the marker combination is applicable to preparation of diagnostic kits, construction of disease prediction models and development of targeted therapy drugs, and a theoretical basis is provided for early discovery, risk early warning and advanced intervention of the HIV combined with the non-alcoholic fatty liver disease.

The invention relates to the technical field of bioinformatics and medical artificial intelligence data processing, in particular to a colorectal cancer risk assessment system based on intestinal microbiological diversity, which comprises a multi-modal time sequence data acquisition module, a multi-modal time sequence data acquisition module, a target object microbiome time sequence feature data acquisition module and a target object microbiome time sequence feature data acquisition module, obtaining current medical resource load state parameters; the compliance entropy calculation module is used for resolving longitudinal compliance entropy representing the data uploading continuity willingness of the target object; the artifact interference identification module is used for generating a physiological disturbance probability value and a denoised pathological evolution feature vector; the double-constraint risk assessment module is used for calculating an initial pathological risk index of the target object; the dynamic decision scheduling module is used for determining a final dynamic intervention strategy for the target object; according to the method, the false positive and false alarm rate is remarkably reduced, and the technical pain point that real pathological evolution and environmental interference are difficult to distinguish by a traditional method is solved.

The present invention relates to a composition for alleviating obesity, improving cognitive function and memory, and preventing Alzheimer's disease, comprising a fermented hemp seed product as an active ingredient. The fermented hemp seed product prepared by inoculating a Pediococcus acidilactici OHSI1 strain (deposit number: KCTC 15831BP) strain, of the present invention, has the effects of: increasing the abundance and diversity of intestinal microorganisms; increasing beneficial intestinal bacteria; reducing harmful intestinal bacteria; alleviating intestinal microbial flora imbalance; anti-obesity; antioxidation; and controlling Alzheimer's disease-associated enzyme activity, and thus can be effectively used as a food composition or a pharmaceutical composition for preventing, alleviating, or treating obesity or cognitive dysfunction, and as a health functional food composition for improving memory and cognitive function by improving intestinal microbial flora.

The invention discloses application of a combination of probiotics GOLDGUT-M520 and GOLDGUT-LR99 in preparation of a product for relieving depression, and belongs to the technical field of biological medicines. The probiotics disclosed by the invention can be used for relieving depressive symptoms, improving related symptoms, assisting in treating depression and preventing depression, and also can be used as a nutritional supplement to help maintain the balance of intestinal microflora and promote intestinal health.

The invention provides application of bacillus tequilensis Bt-CO as a feed additive in largemouth bass culture, and belongs to the technical field of largemouth bass culture. The preservation number of the bacillus tequilensis Bt-CO is GDMCC No: 64960, the influence of the Bt-CO on the growth, survival, physical signs, immunity, antioxidant reaction, digestive enzyme, disease resistance, intestinal microbiota and metabolism of the largemouth bass is evaluated, and the probiotic potential of the Bt-CO and the effect of the Bt-CO in enhancing the resistance of the largemouth bass to aeromonas veronii infection are proved; bt-CO can be developed into a substitute of antibiotics, and a theoretical framework and a practical basis are provided for reasonable application of probiotics in aquaculture.

The present invention provides a compound of Formula (I), which can be used to prepare a composition for losing weight and improving gut microbiota composition. The invention also provides a composition comprising an effective amount of the compound, which has the ability to increase the abundance of Bacteroidales, thereby reducing the ratio of Firmicutes to Bacteroidetes, and can increase the abundance of beneficial gut bacteria and change the gut microbiota composition. The compound and composition of the invention can be applied in food, medicine, feed, nutritional supplements and other uses.

The invention relates to the technical field of medical assistance, in particular to a depression risk assessment method and system based on intestinal flora characteristics. The method comprises the following steps: acquiring an individual enteric microorganism sample, performing nucleic acid sequencing on the enteric microorganism sample, and determining abundance data of functional genes related to a neural activity metabolic pathway in enteric microorganisms; carrying out metabolite detection on the intestinal microorganism sample, and determining concentration data of metabolites related to the neural activity metabolic pathway in the intestinal microorganisms; based on the abundance data of the functional genes and the concentration data of the metabolites, data fusion processing is carried out, a neural activity metabolism function spectrum is constructed, and the neural activity metabolism function spectrum is a multi-dimensional feature vector; and inputting the neural activity metabolic function spectrum into a pre-trained risk assessment model, and outputting a depression risk score of the individual. The accuracy and repeatability of evaluation are remarkably improved, and the method has great potential for early screening, dynamic monitoring and personalized health management.

The invention discloses a liver cirrhosis microbial marker as well as a screening method and application thereof, and solves the technical problems of few markers, small clinical queue scale and unknown effectiveness in predicting the future liver cirrhosis risk in the existing intestinal flora biomarker research. The method comprises the following steps: by integrating whole genome association research data (GWAS) and 16S rRNA gene sequencing data, screening out candidate microbial differential bacteria related to liver cirrhosis by adopting difference analysis; in combination with LDSC analysis and a double-sample Mendel randomization method, MR related bacteria and LDSC genetic related bacteria are screened from the aspects of causal correlation and genetic correlation; taking an intersection of the differential bacteria, the MR related bacteria and the LDSC genetic related bacteria as a marker; finally, model training is conducted through a machine learning algorithm by means of a data set with sample labels, individual liver cirrhosis risk prediction labels are output, early screening of liver cirrhosis is achieved, and the method can be widely applied to the technical field of intestinal microorganism and data mining.

This invention belongs to the field of intestinal microbiome technology, specifically relating to a capsular polysaccharide derived from Bacteroides salorlis CSP6, its preparation method, and its applications. The monosaccharide composition of the capsular polysaccharide is mainly composed of fucose, glucose, and glucosamine, with a molecular weight of 7.139 × 10⁻⁶. 5 The strain described is deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M20221993. In vitro studies have found that the capsular polysaccharide derived from Bacteroides Salieris CSP6 can inhibit α-glucosidase; in vivo animal experiments have demonstrated that this capsular polysaccharide can inhibit the rise in postprandial blood glucose and has a hypoglycemic effect.

The present invention relates to a method for identifying immune-related microorganisms in colorectal cancer based on multi-omics features, and belongs to the field of biomedicine technology. The method includes analyzing the diversity and composition of intestinal flora in colorectal cancer patients and healthy controls; identifying intestinal microorganisms significantly associated with patients through the LASSO algorithm; selecting characteristic intestinal microorganisms of colorectal cancer by the SVM-RFE method; obtaining overlapping genes between the two algorithms, and incorporating the overlapping genes into ROC and DCA analysis verification; the method includes screening key microorganisms for immune regulation, predictive analysis of immune-related intestinal microbial functions, analysis of immune-related microorganisms and immune microenvironment, and prediction of the mechanism of action of immune-related intestinal microorganisms; the method of the present invention can screen out key microorganisms with immune regulatory effects in colorectal cancer, laying the foundation for studying the mechanism of action of intestinal flora and formulating personalized precision medication plans.

The utility model discloses an automatic microorganism enrichment and adsorption device and relates to the technical field of biomedicine. The device comprises an enrichment adsorption box, the enrichment adsorption box is provided with a harmful bacterium adsorption assembly used for removing harmful bacteria in intestinal microorganism mixed liquid, a beneficial bacterium enrichment assembly used for enriching beneficial bacteria in the microorganism mixed liquid, a beneficial bacterium dissociation assembly used for dissociating the beneficial bacteria and antibody magnetic beads which are coupled together, and a beneficial bacterium collection bottle used for collecting the beneficial bacteria. And the negative pressure assembly is used for enabling the intestinal microorganism mixed liquid to flow through the harmful bacterium adsorption assembly, the beneficial bacterium enrichment assembly and the beneficial bacterium dissociation assembly and enter the beneficial bacterium collection bottle. According to the utility model, specific intestinal microorganisms can be selectively screened, so that a solid foundation is laid for precise transplantation of intestinal flora and precise treatment of specific related diseases of the intestinal tract.

The invention relates to nutritional compositions for infants and in particular formulae for infants comprising human milk oligosaccharides, specific bifidobacteria, and urea as non-protein nitrogen source for improving the intestinal microbiota.

The present disclosure provides freeze-dried and liquid compositions that include an extract of human feces. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's intestinal microbiota, and methods for treating a disease or condition such as hepatic encephalopathy.

The microorganism strain Pediococcus acidilactici TAK 589 CoccobEst is a new antimicrobial and antioxidant probiotic, CoccobEst inhibits the growth of the enteropathogens L. monocytogenes, E. coli, S. enteritidis, S. typhimurium, S. sonnei, S. aureus, E. faecalis and C. sakazakii, but does not inhibit lactobacilli of natural intestinal microbiota. The strain's antimicrobial properties are enhanced by periplasmic peptidoglycan hydrolases with proteolytic activity. CoccobEst is used as a zootechnieai feed additive to prevent bacterial infections in the gastrointestinal tract of farm animals and pets and to prevent and reduce diarrhea. CoccobEst has highly active antioxidant defense system, increasing the redox activity of glutathione and reducing oxidative stress in cells. Therefore, CoccobEst is used as a food supplement or functional food for humans to prevent bacterial infections of the gastrointestinal tract and to prevent and reduce oxidative stress. In addition, CoccobEst is used as a starter culture in fermentation of vegetables.

The invention belongs to the technical field of soil remediation, and relates to a method for remediating norfloxacin contaminated soil by using earthworm intestinal contents, which comprises the following steps: inducing earthworms to empty the intestinal contents on quartz sand by illumination, extracting by using a phosphate buffer solution, activating nutrient solution and treating by using a modifier to obtain high-activity modified earthworm intestinal contents, and granulating with activated carbon, organic acid and mineral materials according to a specific ratio, and embedding and curing to prepare the repairing agent. After the remediation agent is applied to the contaminated soil, efficient decomposition of norfloxacin and synchronous restoration of the ecological function of the soil are achieved through the degradation effect of earthworm intestinal microorganisms, the adsorption effect of activated carbon, the complex reaction of organic acid and physical regulation and control of mineral materials. The method creatively utilizes natural microbial communities in the intestinal tract of the earthworm, has the advantages of thorough degradation, environmental compatibility, low cost, simplicity and convenience in operation and the like, and effectively overcomes the problems of chemical residues, poor microbial adaptability, long repair period and the like in a traditional repair method.

The invention provides a risk prediction method and device based on digestive system department diseases, and the method comprises the steps: obtaining clinical data and intestinal microbiome data of a target object, and carrying out the preprocessing and standardization of a clinical data set and the intestinal microbiome data; inputting the preprocessed clinical data into a first encoder to obtain a clinical feature matrix; inputting the preprocessed intestinal microbiome into a second encoder to obtain an intestinal microbiome characteristic matrix; based on a cross-modal attention mechanism, performing bidirectional attention calculation on the clinical feature matrix and the intestinal microbiome feature matrix to obtain fusion features; the method comprises the following steps: performing two-way interaction and fusion on clinical data and microbiome data of a target object, calculating an SHAP value of a fusion feature, taking the fusion feature as an input of a preset risk prediction module, and obtaining a risk prediction value of a disease of the digestive system department, and obtaining the risk prediction value of the disease of the digestive system department through two-way interaction and fusion of the clinical data and the microbiome data of the target object. The method can assist doctors in interpreting which key clinical indexes or intestinal microorganism characteristics have relatively large multi-risk prediction influence, assist clinical decision, and further improve the interpretability of digestive system department disease risk prediction.

The disclosure relates to anti-inflammatory, oxygen-scavenging membrane vesicles derived from bacteria with modified or absent lipopolysaccharide. The disclosure further relates to pharmaceutical and nutritional compositions comprising these vesicles, and methods of using the same. Methods include therapeutic treatment of diseases associated with gut oxygenation and inflammation, such as inflammatory bowel disease, as well as non-therapeutic methods for supporting gastrointestinal health, promoting a healthy inflammatory response, and maintaining a balanced gut microbiota.

The present invention concerns nutritional compositions comprising a mixture of non-digestible oligosaccharides consisting of a combination of 5 specific human milk oligosaccharides, beta-galacto-oligosaccharides and long chain fructo-oligosaccharides (lcFOS). The nutritional compositions are of benefit for improving intestinal microbiota.

The invention provides rhizoma alismatis purified polysaccharide as well as a preparation method, an identification method and application thereof, the rhizoma alismatis purified polysaccharide is a functional component with a novel structure in a traditional Chinese medicine rhizoma alismatis water extract obtained by further extraction and purification, the administration efficiency is effectively improved, and the pharmacodynamic substances are clarified; in-vivo and in-vitro experiments show that the polysaccharide can improve the antioxidant capacity of the liver and relieve inflammatory response; synthesis and metabolism of liver bile acid can be adjusted, cholestasis of the liver is relieved, and bile acid circulation is promoted so as to relieve acute liver injury caused by acetaminophen; the effect of promoting the recovery of liver injury patients is obvious; and the compound also can be used as prebiotics to improve the homeostasis of intestinal microorganisms and promote the synthesis of short-chain fatty acids so as to have beneficial effects on the liver.

The application discloses application of lactobacillus reuteri 202212 in promoting growth and development of lambs, and belongs to the technical field of microorganism application, and particularly relates to application of lactobacillus reuteri 202212 in promoting growth and development of lambs. Lactobacillus reuteri The lactobacillus reuteri 202212 is preserved in the China General Microbiological Culture Collection Center on April 26, 2022, and the preservation address is No. 1, Xibaixili, Chaoyang District, Beijing, and the preservation number is CGMCC No. 24773. The lactobacillus reuteri 202212 disclosed by the application can promote growth and development of lambs, regulate intestinal microorganism flora of lambs, and enhance immune function of lambs.